New study tracks how sickle cell drug affects puberty and fertility

NCT ID NCT07116772

Recruiting now Knowledge-focused Sponsor: Children's Hospital Medical Center, Cincinnati Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

The SAFE study is a long-term research project following 250 adolescents and young adults with sickle cell anemia. It aims to understand how the medicine hydroxyurea affects growth, puberty, and the ability to have children. Researchers will also compare pregnancy outcomes between those who take hydroxyurea and those who do not.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: hydroxyurea
What this could lead to: If successful, this study could clarify how hydroxyurea affects growth, puberty, and fertility in people with sickle cell anemia, helping guide safer long-term use.
What could go wrong: This is an observational study, not a treatment trial. It will not test new therapies or directly improve outcomes. Results may take years and may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SICKLE CELL ANEMIA

Contacts and locations

Locations

Buganda Medical Centre
RECRUITING

Mwanza, Tanzania
Caribbean Institute for Health Research, University of West Indies
RECRUITING

Kingston, Jamaica
Centro de Obstetricia y Ginecologia
RECRUITING

Santo Domingo, Dominican Republic

More trials for these conditions

Other studies related to the condition(s) this trial covers.